natgillin/translations-raw huggingface dataset:
The use of ABASAGLAR may be considered during pregnancy, if clinically needed. 
Med nosečnostjo lahko pride v poštev uporaba zdravila ABASAGLAR, če je klinično potrebna.
• If you cannot remove the pen cap, gently twist the cap back and forth, and then pull the cap straight off. 
• Če ne morete odstraniti pokrovčka peresnika, nežno zavrtite pokrovček nazaj in naprej in ga nato potegnite naravnost navzdol.
In patients with type 2 diabetes mellitus, ABASAGLAR can also be given together with orally active antidiabetic medicinal products. 
Pri bolnikih z diabetesom mellitusom tipa 2 je mogoče zdravilo ABASAGLAR uporabljati tudi skupaj s peroralnimi antidiabetičnimi zdravili.
Choose your injection site. 
Izberite mesto injiciranja.
Store below 30 º C. 
Shranjujte pri temperaturi do 30 º C.
Pentamidine (used to treat some infections caused by parasites) may cause hypoglycaemia which may sometimes be followed by hyperglycaemia. 
Pentamidin (uporablja se za zdravljenje nekaterih okužb, ki jih povzročijo zajedavci) lahko povzroči hipoglikemijo, ki ji včasih sledi hiperglikemija.
There were no differences between insulin glargine and standard care for the two coprimary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome. 
Med insulinom glargin in standardnim zdravljenjem ni bilo razlik glede dveh primarnih izidov, glede katere koli komponente opazovanega dogodka, ki je vključevala te izide, glede celokupne smrtnosti in glede sestavljenega mikrovaskularnega izida.
If you have any questions or problems with your ABASAGLAR KwikPen, contact your healthcare professional for assistance. 
Če imate vprašanja ali težave z vašim injekcijskim peresnikom ABASAGLAR KwikPen, se za pomoč obrnite na svojega zdravstvenega delavca.
* Insulin glargine is produced by recombinant DNA technology in Escherichia coli. 
*Insulin glargin je pridobljen s tehnologijo rekombinantne DNA iz bakterij Escherichia coli.
Not all of these pens may be marketed in your country. 
V vaši državi na trgu morda ni vseh navedenih peresnikov.
Other medicines and ABASAGLAR 
Druga zdravila in zdravilo ABASAGLAR
Switch from other insulins to ABASAGLAR 
Prehod z drugih insulinov na zdravilo ABASAGLAR
Stomach pain, fast and deep breathing, sleepiness or even loss of consciousness may be signs of a serious condition (ketoacidosis) resulting from lack of insulin. 
zaspanost ali celo izguba zavesti pa so lahko znaki resnega stanja (ketoacidoze), ki se pojavi zaradi pomanjkanja insulina.
It is unknown whether insulin glargine is excreted in human milk. 
Ni znano, ali se insulin glargin izloča v materino mleko.
Pharmacotherapeutic group: Drugs used in diabetes, insulins and analogues for injection, long-acting. 
Farmakoterapevtska skupina: Zdravila za zdravljenje diabetesa, insulini za injiciranje z dolgotrajnim delovanjem in analogi.
Hypoglycaemia (low blood sugar) can be very serious and is very common with insulin treatment (may affect more than 1 in 10 people). 
Hipoglikemija (nizka koncentracija krvnega sladkorja) je lahko zelo resna in je pri zdravljenju z insulinom zelo pogosta (pojavi se lahko pri več kot 1 od 10
Change the injection site with each injection to help prevent these skin changes. 
Mesto injiciranja pri vsaki injekciji zamenjajte, da preprečite te kožne spremembe.
What you need to know before you use ABASAGLAR Do not use ABASAGLAR 
Kaj morate vedeti, preden boste uporabili zdravilo ABASAGLAR Ne uporabljajte zdravila ABASAGLAR
Do not try to inject your insulin by turning the dose knob. 
Ne poskušajte si injicirati insulina z obračanjem gumba za odmerjanje.
This medicine contains less than 1 mmol (23 mg) sodium per dose, which means it is essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni “brez natrija”.
Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. 
Insulin in njegovi analogi znižujejo koncentracijo glukoze v krvi s spodbujanjem perifernega privzema glukoze, zlasti v skeletnem mišičju in maščevju, ter z zaviranjem tvorbe glukoze v jetrih.
• You can give from 1 to 6080 units in a single injection. 
• Z eno injekcijo lahko dozirate od 1 do 60 80 enot.
Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angiooedema, bronchospasm, hypotension and shock, and may be life-threatening. 
Takšne reakcije na insulin (tudi na insulin glargin) ali pomožne snovi so lahko povezane tudi npr. z generaliziranimi kožnimi reakcijami, angioedemom, bronhospazmom, hipotenzijo in šokom ter so lahko smrtno nevarne.
In clinical studies, subgroup analyses based on age and gender did not indicate any difference in safety and efficacy in insulin glargine-treated patients compared to the entire study population. 
Analize podskupin po starosti in spolu v kliničnih študijah niso pokazale razlik v varnosti in učinkovitosti pri bolnikih, zdravljenih z insulinom glargin, v primerjavi s celotno raziskovano populacijo.
As with all insulins, the time course of action of insulin glargine may be affected by physical activity and other variables. 
Na časovni potek delovanja insulina glargin lahko, tako kot pri vseh insulinih, vplivajo telesna dejavnost in drugi spremenljivi dejavniki.
If the insulin pen is damaged or not working properly (due to mechanical defects) it has to be discarded, and a new insulin pen has to be used. 
Če je insulinski peresnik poškodovan ali če ne deluje pravilno (zaradi mehanskih okvar), ga morate zavreči in uporabiti nov insulinski peresnik.
Store below 30 º C. Do not refrigerate or freeze. 
Shranjujte pri temperaturi do 30 º C. Ne shranjujte v hladilniku in ne zamrzujte.
Hold the dose knob in and count to 5 slowly. 
Gumb za odmerjanje pritiskajte navznoter in počasi štejte do pet.
• Pull off the inner needle shield and throw it away. 
• Odstranite zaščito notranje igle in jo zavrzite.
Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia. 
Intravenska aplikacija običajnega subkutanega odmerka lahko povzroči hudo hipoglikemijo.
The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycaemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. 
Primarni cilj, dokazati neinferiornost insulina glargin v primerjavi z insulinom NPH v zvezi z hipoglikemijami, ni bil dokazan - opazen je bil trend povečanja hipoglikemičnih dogodkov z insulinom glargin [razmerje insulin glargin : NPH (95 % IZ) = 1,18 (0,97-1,44)].
In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered. 
V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiperglikemijam ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustrezno tehniko injiciranja in vse druge pomembne dejavnike.
ABASAGLAR should look clear and colourless. 
Zdravilo ABASAGLAR mora biti na pogled bistro in brezbarvno.
Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim, France. 
Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim, Francija.
ABASAGLAR is a biosimilar medicinal product. 
Zdravilo ABASAGLAR je biološko podobno zdravilo.
EXP Discard 28 days after first use. 
EXP Peresnik zavrzite 28 dni po prvi uporabi.
Combination of ABASAGLAR with pioglitazone 
Kombinacija zdravila ABASAGLAR in pioglitazona
Very rare side-effects (may affect up to1 in 10,000 people) In very rare cases, dysgeusia (taste disorders) and myalgia (muscular pain) can occur. 
Zelo redko poročani neželeni učinki (pojavijo se lahko pri največ 1 od 10.000 bolnikov) V zelo redkih primerih se lahko pojavita disgevzija (motnje okušanja) in mialgija (bolečine v mišicah).
In a randomised, controlled clinical study, paediatric patients (age range 6 to 15 years) with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. 
Pediatrična populacija V randomizirani, kontrolirani klinični študiji so pediatrične bolnike (stare od 6 do 15 let) s sladkorno boleznijo tipa 1 (n=349) 28 tednov zdravili z bazalno-bolusnim insulinskim režimom, pri katerem je bil pred vsakim obrokom uporabljen navadni humani insulin.
Keep Throw Away 
Obdržite Zavržite
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. 
Pri nekaterih bolnikih z dolgotrajno sladkorno boleznijo tipa 2 in srčno boleznijo ali predhodno kapjo, ki so se zdravili s pioglitazonom in inzulinom, je prišlo do razvoja srčnega popuščanja.
Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections 
natrijev hidroksid (za prilagoditev pH) voda za injekcije
Intercurrent illness requires intensified metabolic monitoring. 
V primeru sočasnih bolezni je potreben intenzivnejši nadzor presnove.
Complaints of injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults. 
O pritožbah zaradi reakcij na mestu injiciranja (bolečina na mestu injiciranja, reakcija na mestu injiciranja) in kožnih reakcij (izpuščaj, urtikarija) so poročali relativno bolj pogosto pri otrocih in mladostnikih, starih 18 let ali manj, kot pri odraslih bolnikih.
Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema). 
Nemudoma obvestite svojega zdravnika, če opazite znake srčnega popuščanja, kot so neobičajno primanjkovanje zraka pri vdihovanju ali naglo povečanje telesne mase ali lokalizirano otekanje (edemi).
Switch from insulin glargine 300 units/ml to ABASAGLAR ABASAGLAR and Toujeo (insulin glargine 300 units/ml) are not bioequivalent and are not directly interchangeable. 
Prehod z insulina glargina 300 enot/ml na zdravilo ABASAGLAR Zdravili ABASAGLAR in Toujeo (insulin glargin 300 enot/ml) nista bioekvivalentni zdravili in nista neposredno medsebojno zamenljivi.
Concentrations were thus consistent with the time profile of the pharmacodynamic activity of insulin glargine. 
Koncentracija se je torej skladala s časovnim potekom farmakodinamičnega delovanja insulina glargin.
Only use needles that are compatible for use with ABASAGLAR KwikPen (see “ABASAGLAR KwikPen Instructions for Use”). 
Uporabljajte le igle, ki so primerne za uporabo s peresnikom ABASAGLAR KwikPen (glejte Navodila za uporabo peresnika ABASAGLAR KwikPen).
Throw the pen away and get a new pen. 
Zavrzite peresnik in vzemite novega.
A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. 
Večja količina podatkov o nosečnicah (več kot 1.000 izidov nosečnosti) ne kaže nobenih posebnih neželenih učinkov insulina glargin na nosečnost; prav tako ne kaže, da bi insulin glargin povzročal posebne malformacije, fetotoksične učinke ali toksične učinke na novorojenčka.
The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure (coronary, carotid, or peripheral), or hospitalisation for heart failure. 
Prvi primarni izid učinkovitosti je bil čas do prvega pojava srčno-žilne smrti, neusodnega miokardnega infarkta (MI), neusodne možganske kapi, drugi primarni izid učinkovitosti pa je bil čas do prvega pojava katerega koli od prvih primarnih dogodkov, do revaskularizacijskega posega (koronarni,
Contents of the pack and other information What ABASAGLAR contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo ABASAGLAR
Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. 
Insulin glargin je analog humanega insulina, pripravljen tako, da je pri nevtralnem pH slabo topen.
More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. 
Hujše primere s komo, generaliziranimi krči ali nevrološko prizadetostjo je mogoče zdraviti z glukagonom intramuskularno ali subkutano oz. s koncentrirano glukozo intravensko.
- You may have dust, food, or liquid inside the pen. 
- morda se je v notranjosti peresnika nabral prah, hrana ali tekočina.
• Do not store the pen with the needle attached to prevent leaking, blocking the needle, and air from entering the pen. 
Peresnika ne shranjujte s privito iglo, da preprečite puščanje, zamašitev igle in vstop zraka v peresnik.
Dose adjustment may also be required, for example, if the patient's weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see section 4.4). 
Prilagoditev odmerka je lahko potrebna tudi, če se npr. spremeni bolnikova telesna masa, način življenja ali čas apliciranja insulina, ali se pojavijo kakšne druge okoliščine, ki povečajo nagnjenost k hipoglikemiji ali hiperglikemiji (glejte poglavje 4.4).
Each cartridge contains 3 mL of solution for injection (equivalent to 300 units) and they are available in packs of 5 and 10 cartridges. 
Vsak vložek vsebuje 3 ml raztopine za injiciranje (kar ustreza 300 enotam), na voljo pa so v pakiranjih po 5 in 10 vložkov.
Due to more sustained basal insulin supply with insulin glargine, less nocturnal but more early morning hypoglycaemia can be expected. 
Zaradi enakomernejšega sproščanja bazalnega insulina je pri insulinu glargin mogoče pričakovati manj nočnih, a več zgodnjih jutranjih hipoglikemij.
In general, the side effects in children and adolescents of 18 years of age or less are similar to those seen in adults. 
Navadno so neželeni učinki pri otrocih in mladostnikih starih < 18 let podobni neželenim učinkom pri odraslih.
3 mL solution in a cartridge (type 1 colourless glass) with a plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl rubber) with aluminium seal. 
3 ml raztopine v vložku (iz brezbarvnega stekla tipa 1) z batom (iz halobutilne gume) in zaporno ploščico (iz poliizoprenskega laminata in halobutilne gume) z aluminijasto zaporko.
What ABASAGLAR is and what it is used for 
Kaj je zdravilo ABASAGLAR in za kaj ga uporabljamo
Thirst, increased need to urinate, tiredness, dry skin, reddening of the face, loss of appetite, low blood pressure, fast heartbeat, and glucose and ketone bodies in urine. 
Žeja, pogostejše siljenje na vodo, utrujenost, suha koža, pordelost obraza, izguba teka, nizek krvni tlak, hitro bitje srca ter glukoza in ketoni v urinu.
• Pull the needle out of your skin. 
Izvlecite iglo iz kože.
In use 
V uporabi
• Skin changes at the injection site 
• Spremembe kože na mestu injiciranja
The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type 1 diabetic patients was markedly lower than what would be required for a half maximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor. 
Celotna terapevtska koncentracija insulina (insulina glargina in njegovih presnovkov) je bila pri bolnikih s sladkorno boleznijo tipa 1 bistveno manjša od koncentracije, potrebne za polovično največjo zasedenost receptorjev za IGF-1 in posledično aktivacijo mitogeno-proliferacijske poti, ki jo sproža receptor za IGF-1.
The medicinal product may be stored for a maximum of 28 days up to 30°C and away from direct heat or direct light. 
Zdravilo lahko shranjujete največ 28 dni pri temperaturi do 30 °C in zaščiteno pred neposredno toploto ali svetlobo.
One hundred forty three of the patients treated with insulin glargine in this study continued treatment with insulin glargine in an uncontrolled extension study with mean duration of follow-up of 2 years. 
Sto triinštirideset (143) bolnikov, ki so v tej študiji uporabljali insulin glargin, je zdravljenje z njim nadaljevalo v nekontrolirani podaljšani študiji, v kateri je povprečno spremljanje trajalo 2 leti.
Correspondingly, the incidences of nocturnal hypoglycaemia were 32 % in the insulin glargine / lispro group vs. 52 % in the NPH / regular group. 
Ustrezno so bile incidence nočne hipoglikemije 32-% v skupini z insulinom glargin/insulinom lispro, v skupini z insulinom NPH/redni skupini pa 52-%.
Immediately take about 10 to 20 g sugar, such as glucose, sugar cubes or a sugar-sweetened beverage. 
Nemudoma zaužijte približno 10 do 20 gramov sladkorja, v obliki glukoze,
Do not mix ABASAGLAR with any other insulins or medicines. 
Ne mešajte zdravila ABASAGLAR z nobenim drugim insulinom ali zdravili.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of insulin glargine. 
Farmakokinetični in farmakodinamski izsledki kažejo, da učinek subkutano injiciranega insulina glargin temelji predvsem na izpostavljenosti presnovku M1. Insulin glargin in presnovek M2 pri veliki večini preiskovancev nista bila zaznavna; če sta bila zaznavna, pa njuna koncentracija ni bila odvisna od uporabljenega odmerka insulina glargin.
Rarely, insulin may cause sodium retention and oedema particularly if previously poor metabolic control is improved by intensified insulin therapy. 
Redko lahko insulin povzroči zadrževanje natrija in edeme, še zlasti, če intenzivirano insulinsko zdravljenje izboljša presnovno urejenost, ki je bila prej slaba.
Insulin glargine was administered once daily at bedtime and NPH human insulin was administered once or twice daily. 
Insulin glargin so uporabljali enkrat na dan pred spanjem, humani insulin NPH pa enkrat ali dvakrat na dan.
Prolonged or severe hypoglycaemic episodes may be life-threatening. 
Dolgotrajne ali hude hipoglikemije so lahko smrtno nevarne.
Participants were randomised (1:1) to receive insulin glargine (n=6,264), titrated to reach FPG ≤95 mg/dL (5.3 mM), or standard care (n=6,273). 
Preiskovanci so po randomizaciji (1:1) prejemali insulin glargin (n=6264), titriran tako, da so dosegli FPG ≤95 mg/dl (5,3 mM), ali standardno zdravljenje.
Figure 1 above shows the activity profiles over time of insulin glargine and NPH insulin. 
Slika 1 zgoraj prikazuje časovni potek delovanja insulina glargin in insulina NPH.
If you forget to use ABASAGLAR 
Če ste pozabili vzeti zdravilo ABASAGLAR
Before using ABASAGLAR solution for injection in pre-filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6). 
Pred uporabo zdravila ABASAGLAR raztopina za injiciranje v napolnjenem injekcijskem peresniku morate pozorno prebrati Navodila za uporabo na vloženem lističu (glejte poglavje 6.6).
Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. 
Pentamidin lahko povzroči hipoglikemijo, ki ji včasih sledi hiperglikemija.
If you notice signs of your blood sugar being too low (hypoglycaemia), take the action to increase your blood sugar levels inmediately. 
Če opazite znake prenizkega krvnega sladkorja (hipoglikemije), takoj ukrepajte, da si zvišate dvignete koncentracijo krvnega sladkorja.
• Store the pen you are currently using at room temperature [below 30 ° C] and away from heat and light. 
• Peresnik, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi [do 30 °C] in zaščitenega pred toploto in svetlobo.
Instead, regular insulin administered intravenously is recommended in such cases. 
V takšnih primerih je treba uporabiti običajni insulin, apliciran intravensko.
Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or using machines). 
Ne pozabite na to v okoliščinah, v katerih bi lahko ogrozili sebe in druge (kot sta vožnja avtomobila ali uporaba strojev).
At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up. 
Ob izhodišču so imeli preiskovanci mediano vrednost HbA1c 6,4 %, mediane vrednosti HbA1c med zdravljenjem pa so bile med 5,9 in 6,4 % v skupini z insulinom glargin in med 6,2 in 6,6 % v skupini s standardnim zdravljenjem ves čas spremljanja, Stopnji hude hipoglikemije (prizadeti preiskovanci na 100
In rare cases, insulin treatment may also cause temporary build-up of water in the body, with swelling in the calves and ankles. 
V redkih primerih zdravljenje z insulinom povzroči tudi prehodno zadrževanje vode v telesu in posledično otekanje meč in gležnjev.
In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 5.1). 
V redkih primerih je zaradi obstoja takšnih protiteles proti insulinu treba prilagoditi odmerek insulina, da bi odpravili nagnjenost k hiperali hipoglikemiji (glejte poglavje 5.1).
In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were similar after intravenous insulin glargine and human insulin both in healthy volunteers and patients with type 1 diabetes. 
V klinični študiji so bili simptomi hipoglikemije in protiregulacijski hormonski odzivi po intravenski uporabi insulina glargin in humanega insulina pri zdravih prostovoljcih in bolnikih z diabetesom tipa 1 podobni.
How to store ABASAGLAR Contents of the pack and other information 
Shranjevanje zdravila ABASAGLAR Vsebina pakiranja in dodatne informacije
• Check the number in the dose window 
Preverite številko v okencu za prikaz odmerka
This could lead to severe hyperglycaemia (very high blood sugar) and ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). 
Če ste prenehali jemati zdravilo ABASAGLAR To lahko vodi v hudo hiperglikemijo (zelo visok krvni sladkor) in ketoacidozo (kopičenje kisline v krvi, ker telo presnavlja maščobe namesto sladkorja).
- The dose knob clicks as you turn it. - DO NOT dial your dose by counting the clicks because you may dial the wrong dose. 
- NE nastavite svojega odmerka s štetjem klikov, saj bi lahko nastavili napačen odmerek.
• Prepare your skin as recommended by your healthcare professional. 
Pripravite kožo, kot vam je to priporočil vaš zdravnik.
- You should use a new needle for each injection and repeat the priming step. 
- Za vsako injiciranje morate uporabiti novo iglo in ponoviti aktivacijo peresnika.
Before injection remove any air bubbles (see instructions for using the pen). 
Pred injiciranjem odstranite vse zračne mehurčke (glejte navodila za uporabo peresnika).
Insulin glargine did not alter the relative risk for CV disease and CV mortality when compared to standard of care. 
Insulin glargin v primerjavi s standardnim zdravljenjem ni spremenil relativnega tveganja za srčnožilno bolezen in srčno-žilno smrtnost.